drugset / Trial / NCT00154635
Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
Phase 2
Unknown
80 enrolled
National Taiwan University Hospital
Development Center for Biotechnology, Taiwan · collabProgram Office, National Science & Technology, Biotechnology & Pharmaceuticals · collabTaipei Veterans General Hospital, Taiwan · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCB-AD1 | Traditional medicine (herbal / TCM) | — | — |